Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: A multicenter confirmatory study

Stroke

Volumn 38, Issue 6, 2007, Pages 1855-1859

  Castellanos, Mar ^a   Sobrino, Tomás ^b   Millán, Mónica ^c   García, María ^a   Arenillas, Juan ^c   Nombela, Florentino ^d   Brea, David ^b   Perez De La Ossa, Natalia ^c   Serena, Joaquín ^a   Vivancos, José ^d   Castillo, José ^b   Dávalos, Antoni ^c,e  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Biomarkers; Blood brain barrier; Hemorrhage; Metalloproteinases; Stroke; Thrombolytic therapy

Indexed keywords

BIOLOGICAL MARKER; DISUFENTON SODIUM; FIBRONECTIN; GELATINASE B; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BRAIN HEMATOMA; BRAIN HEMORRHAGE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PARENCHYMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RATING SCALE; SENSITIVITY AND SPECIFICITY; UNIVERSITY HOSPITAL; VALIDATION PROCESS;

AGED; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FEMALE; FIBRONECTINS; HEMATOMA, EPIDURAL, CRANIAL; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; THROMBOLYTIC THERAPY;

EID: 34249822233     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.106.481556     Document Type: Article

References (15)

1. Bateman BT, Schumacher HC, Boden-Albala B, Berman MF, Mohr JP, Sacco RL, Pile-Spellman J. Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: an analysis of the nationwide inpatient sample 1999 to 2002. Stroke. 2006;37:440-446.
2. Weintraub MI. Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire. Stroke. 2006;37:1917-1922.
3. Larrue V, von Kummer R, Müller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001;32:438-441.
4. Barber PA, Demchuck AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy: ASPECTS study group; Alberta Stroke Program Early CT Score. Lancet. 2000; 355:1670-1674.
5. Selim M, Fink JN, Kumar S, Caplan LR, Horkan C, Chen Y, Linfante I, Schlaug G. Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume. Stroke. 2002;33:2047-2052.
6. Cocho D, Borrell M, Martí-Fàbregas J, Montaner J, Castellanos M, Bravo Y, Molina-Porcel L, Belvís R, Diaz-Manera JA, Martínez-Domeño A, Martínez-Lage M, Millán M, Fontcuberta J, Martí-Vilalta JL. Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator. Stroke. 2006;37:996-999.
7. Montaner J, Alvarez-Sabín J, Molina C, Angles A, Abilleira S, Arenillas J, Gonzales MA, Monasterio J. Matrix metalloproteinase expression after human cardioembolic stroke. Stroke. 2001;32:1759-1766.
8. Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, Castillo J, Dávalos A. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke. 2003;34:40-46.
9. Montaner J, Molina C, Monasterio J, Abilleira S, Arenillas J, Ribó J, Quintana M, Alvarez-Sabín J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003;107:598-603.
10. Castellanos M, Leira R, Serena J, Blanco M, Pedraza S, Castillo J, Dávalos A. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke. 2004;35:1671-1676.
11. Wang X, Tsuji K, Lee S-R, Ning M, Furie KL, Buchan AM, Lo EH. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke. 2004;35(suppl I): 2726-2730.
12. Lees KR, Zivin JA, Ashwood T, Dávalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW. Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354: 588-600.
13. Molina C, Alvarez-Sabin J, Montaner J, Abilleira S, Arenillas J, Coscojuela P, Romero F, Codina A. Thrombolysis-related hemorrhagic infarction (HI1-HI2): a marker of early reperfusion, reduced infarct size and improved outcome in patients with proximal MCA occlusion. Stroke. 2002;33:1551-1556.
14. von Kummer R. Brain hemorrhage after thrombolysis: good or bad? Stroke. 2002;33:1446-1447.
15. Trouillas P, von Kummer R. Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. Stroke. 2006;37:556-561.